Citrullinated vimentin presented on MHC-II in tumor cells is a target for CD4+ T-Cell-mediated antitumor immunity

Cancer Research

Volumn 76, Issue 3, 2016, Pages 548-560

  Brentville, Victoria A ^a   Metheringham, Rachael L ^a   Gunn, Barbara ^a   Symonds, Peter ^a   Daniels, Ian ^a   Gijon, Mohamed ^a   Cook, Katherine ^a   Xue, Wei ^a   Durrant, Lindy G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; CITRULLINATED ARGINYLSERYLTYROSYLVALYLTHREONYLTHREONYLSERYLTHREONYLARGINYLTHREONYLTYROSYLSERYLLEUCYLGLYCYLSERYLALANYLLEUCYLARGINYLPROPYLSERYLTHREONYLSERINE; CITRULLINATED GLYCYLGLUTAMYLGLUTAMYLSERYLISOLEUCYLSERYLLEUCYLPROPYLLEUCYLPROPYLTHREONYLPHENYLALANYLSERYLSERYLLEUCYLASPARAGINYLLEUCYLGLUTAMIC ACID; CITRULLINATED LEUCYLPROPYLASPARAGINYLPHENYLALANYLSERYLSERYLLEUCYLASPARAGINYLLEUCYLGLUTAMYLTHREONYLASPARAGINYLLEUCYLASPARTYLSERYLLEUCYLPROPYLLEUCINE; CITRULLINATED LYSYLLEUCYLLEUCYLGLUTAMYLGLYCYLGLUTAMYLGLUTAMYLSERYLISOLEUCYLSERYLLEUCYLPROPYLLEUCYLPROPYLTHREONYLPHENYLALANYLSERINE; CITRULLINATED METHIONYLPHENYLALANYLGLYCYLGLYCYLSERYLGLYCYLTHREONYLSERYLSERYLPROPYLSERYLSERYLASPARAGINYLSERYLTYROSYLVALYLTHREONINE; CITRULLINATED PROPYLSERYLTHREONYLSERYLSERYLLEUCYLTYROSYLSERYLSERYLSERYLPROPYLGLYCYLGLYCYLALANYLTYROSYLVALYLTHREONYLSERINE; CITRULLINATED SERYLASPARAGINYLSERYLTYROSYLVALYLTHREONYLTHREONYLSERYLTHREONYLTHREONYLTYROSYLSERYLLEUCYLGLYCYLSERYLALANYLLEUCINE; CITRULLINATED SERYLTYROSYLVALYLTHREONYLTHREONYLSERYLTHREONYLTHREONYLTYROSYLSERYLLEUCYLGLYCYLSERYLALANYLLEUCYLPROPYLSERYLTHREONYLSERINE; CITRULLINATED THREONYLTYROSYLSERYLLEUCYLGLYCYLSERYLALANYLLEUCYLPROPYLSERYLTHREONYLSERYLSERYLLTYROSYLSERINE; CITRULLINATED VALYLTHREONYLTHREONYLSERYLTHREONYLTHREONYLTYROSYLSERYLLEUCYLGLYCYLSERYLALANYLLEUCYLPROPYLSERYLTHREONYLSERINE; CITRULLINATED VIMENTIN; CITRULLINE; EPITOPE; GAMMA INTERFERON; GRANZYME B; HLA DR4 ANTIGEN; LEUCYLPROPYLASPARAGINYLPHENYLALANYLSERYLSERYLLEUCYLASPARAGINYLLEUCYLARGINYLGLUTAMYLTHREONYLASPARAGINYLLEUCYLASPARTYLSERYLLEUCYLPROPYLLEUCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTITUMOR IMMUNITY; ARTICLE; AUTOPHAGY; CANCER IMMUNIZATION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; DRUG BINDING; DRUG POTENCY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM TUMOR; IMMUNITY; IN VIVO STUDY; LONG TERM SURVIVAL; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HUMAN; IMMUNOLOGY; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; METABOLISM; MOLECULAR GENETICS; PANCREATIC NEOPLASMS; PHYSIOLOGY; RANDOMIZATION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CITRULLINE; EPITOPES, B-LYMPHOCYTE; HEK293 CELLS; HELA CELLS; HLA-DR4 ANTIGEN; HUMANS; LUNG NEOPLASMS; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; RANDOM ALLOCATION; TRANSFECTION; VIMENTIN;

EID: 84958212094     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1085     Document Type: Article

References (39)

1. Brahmer JR, Tykodi SS, Chow LQ, HwuWJ, Topalian SL, HwuP, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermottDF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
4. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-Term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30.
5. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, et al. Development of ipilimumab: A novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013;1291:1-13.
6. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
7. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.
8. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588-94.
9. Brandmaier AG, Leitner WW, Ha SP, Sidney J, Restifo NP, Touloukian CE. High-Avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction. J Immunother 2009;32: 677-88.
10. Lauwen MM, Zwaveling S, de Quartel L, Ferreira Mota SC, Grashorn JA, Melief CJ, et al. Self-Tolerance does not restrict the CD4+T-helper response against the p53 tumor antigen. Cancer Res 2008;68:893-900.
11. Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA, et al. Identification of aMHCclass II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol 2000;164:3535-42.
12. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 2012;51 Suppl 5:v3-11.
13. Grunewald J, Eklund A. Role of CD4+ T cells in sarcoidosis. Proc Am Thorac Soc 2007;4:461-4.
14. Coimbra S, Figueiredo A, Castro E, Rocha-Pereira P, Santos-Silva A. The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol 2012;51:389-95
15. Holmdahl R, Klareskog L, Rubin K, Larsson E, Wigzell H. T lymphocytes in collagen II-induced arthritis in mice. Characterization of arthritogenic collagen II-specific T-cell lines and clones. Scand J Immunol 1985;22: 295-306.
16. Ireland JM, Unanue ER. Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J Exp Med 2011;208: 2625-32.
17. Munz C. Antigen processing for MHC class II presentation via autophagy. Front Immunol 2012;3:9.
18. Schmid D, Pypaert M, Munz C. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity 2007;26:79-92.
19. Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Muller M, et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci U S A 2005;102:7922-7.
20. Aichinger M, WuC, Nedjic J, Klein L.Macroautophagy substrates are loaded ontoMHCclass II of medullary thymic epithelial cells for central tolerance. J Exp Med 2013;210:287-300.
21. Green DR, Levine B. To be or not to be? How selective autophagy and cell death govern cell fate. Cell 2014;157:65-75.
22. Jiang Z, Cui Y, Wang L, Zhao Y, Yan S, Chang X. Investigating citrullinated proteins in tumour cell lines. World J Surg Oncol 2013;11:260.
23. Kovats S, Whiteley PE, Concannon P, Rudensky AY, Blum JS. Presentation of abundant endogenous class II DR-restricted antigens by DM-negative B cell lines. Eur J Immunol 1997;27:1014-21.
24. Metheringham RL, Pudney VA, Gunn B, Towey M, Spendlove I, Durrant LG. Antibodies designed as effective cancer vaccines. MAbs 2009;1: 71-85.
25. Feitsma AL, van der Voort EIH, Franken K, el Bannoudi H, Elferink BG, Drijfhout JW, et al. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum 2010;62:117-25.
26. Carrillo-Vico A, Leech MD, Anderton SM. Contribution of myelin autoantigen citrullination to T cell autoaggression in the central nervous system. J Immunol 2010;184:2839-46.
27. Wang L, Chang X, Yuan G, Zhao Y, Wang P. Expression of peptidylarginine deiminase type 4 in ovarian tumors. Int J Biol Sci 2010;6:454-64.
28. Chang X, Han J. Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors. Mol Carcinog 2006;45:183-96.
29. Taneja V, Behrens M, Basal E, Sparks J, Griffiths MM, Luthra H, et al. Delineating the role of the HLA-DR4 "shared epitope" in susceptibility versus resistance to develop arthritis. J Immunol 2008;181: 2869-77.
30. Linnemann C, van BuurenMM, Bies L, VerdegaalEM, Schotte R, Calis JJ, et al. High-Throughput epitope discovery reveals frequent recognition of neoantigens by CD4+ T cells in human melanoma. Nat Med 2015;21:81-5.
31. Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015;520:692-6.
32. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010;207:637-50.
33. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EKM, et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010;207:651-67.
34. Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012; 72:1081-91.
35. Hirschhorn-Cymerman D, Budhu S, Kitano S, Liu C, Zhao F, Zhong H, et al. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med 2012;209:2113-26.
36. Qui HZ, Hagymasi AT, Bandyopadhyay S, St Rose MC, Ramanarasimhaiah R, Menoret A, et al. CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J Immunol 2011;187:3555-64.
37. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumorspecific Th17-polarized cells eradicate large established melanoma. Blood 2008;112:362-73.
38. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010;10:248-56.
39. Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood 2013;121:2402-14.